VolitionRx Limited (NYSE American: VNRX) has highlighted a growing body of clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis. The company released an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter, underscoring the test's potential to transform sepsis management.
Multiple studies have shown that Volition's Nu.Q H3.1 test can distinguish sepsis from non-infectious inflammation, correlate with disease severity, and provide strong prognostic value for outcomes including organ failure and mortality. The company noted that most of the supporting research has been peer reviewed and published, with experts pointing to the consistency of findings across multiple countries and patient populations.
Volition believes its low-cost nucleosome quantification technology could help personalize patient care by identifying elevated H3.1 nucleosome levels as a treatable trait in sepsis management and informing future therapeutic strategies. Sepsis remains a leading cause of death worldwide, and early detection and monitoring are critical for improving patient outcomes.
The announcement comes as part of Volition's broader mission to advance the science of epigenetics. The company is developing and commercializing simple, easy-to-use, cost-effective blood tests to detect and monitor a range of diseases, including some cancers and diseases associated with NETosis. The Nu.Q NETs assay represents a significant step forward in this effort, offering a potential tool for clinicians to better manage sepsis and related conditions.
For more information, visit the company's website at https://volition.com/.
